The dubious effect of milnacipran for the treatment of burning mouth syndrome

Clinical Neuropharmacology

Volumn 34, Issue 4, 2011, Pages 170-173

  Sugimoto, Koreaki ^a  

^a TOHOKU FUKUSHI UNIVERSITY   (Japan)

Author keywords

burning mouth syndrome; General Oral Health Assessment Index; Hamilton Rating Scale for Depression; Medical Outcomes Study's 36 item short form health survey; Milnacipran

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; BROTIZOLAM; DOMPERIDONE; ESTAZOLAM; FLUNITRAZEPAM; MILNACIPRAN; NILVADIPINE; NITRAZEPAM; TRIAZOLAM;

ADULT; AGED; ARTICLE; ATYPICAL ODONTALGIA; BURNING MOUTH SYNDROME; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; DEPRESSION; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; FIBROMYALGIA; GLOSSODYNIA; HAMILTON SCALE; HUMAN; INFARCTION; LACUNAR INFARCTION; MAJOR DEPRESSION; NAUSEA; PAIN ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; TOOTH PAIN; TREATMENT DURATION; VASCULAR DEPRESSION; VASCULAR DISEASE; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; BURNING MOUTH SYNDROME; COMORBIDITY; CYCLOPROPANES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOSSALGIA; HUMANS; JAPAN; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PAIN MEASUREMENT; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS;

EID: 80051549676     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31822511c4     Document Type: Article

References (19)

1. Blasberg B, Greenberg MS. Orofacial pain. In: Greenberg MS, Glick M, Ship JA, eds. Burket's Oral Medicine. 11th ed. Hamilton: BC Decker Inc; 2008.
2. Kirwin JL, Goren JL. Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder. Pharmacotherapy 2005;25:396-410. (Pubitemid 40300327)
3. Briley M. New hope in the treatment ofpainful symptoms in depression. Curr Opin Investig Drugs 2003;4:42-45. (Pubitemid 36253677)
4. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004;24:621-629. (Pubitemid 38585956)
5. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes ofantidepressants. CNS Spectr 2005;10:732-747. (Pubitemid 41443048)
6. Ito M, Kimura H, Yoshida K, et al. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol 2010;33:79-83.
7. Kamata M, Takahashi H, Naito S, et al. Effectiveness of milnacipran for the treatment ofchronic pain: a case series. Clin Neuropharmacol 2004;27:208-210. (Pubitemid 39447215)
8. Kamata M, Naito S, Takahashi H, et al. Milnacipran for the treatment ofchronic pain. Hum Psychopharmacol 2003;18:575-576.
9. Naito M, Suzukamo Y, Nakayama T, et al. Linguistic adaptation and validation of the General Oral Health Assessment Index (GOHAI) in an elderly Japanese population. JPublic Health Dent 2006;66:273-275. (Pubitemid 44968316)
10. Fukuhara S, Ware JE Jr, Kosinski M, et al. Psychometric and clinical tests ofvalidity of the Japanese SF-36 Health Survey. JClin Epidemiol 1998;51:1045-1053. (Pubitemid 28527160)
11. Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 Health Survey foruse in Japan. J Clin Epidemiol 1998;51:1037-1044. (Pubitemid 28527159)
12. Obata H, Saito S, Koizuka S, et al. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in aratmodel ofneuropathic pain. Anesth Analg 2005;100:1406-1410, table ofcontents. (Pubitemid 40577395)
13. Ikeda T, Ishida Y, Naono R, et al. Effects ofintrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. Neurosci Res 2009;63:42-46.
14. Suzuki T, Ueta K, Tamagaki S, et al. Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth Analg 2008;106:1309-1315, table ofcontents. (Pubitemid 351450565)
15. Stamford JA. Descending control ofpain. Br JAnaesth 1995;75:217-227.
16. Stahl SM. The psychopharmacology ofpainful physical symptoms in depression. J Clin Psychiatry 2002;63:382-383. (Pubitemid 34507213)
17. Treister N, Woo SB, AAOM Web Writing Group [American Academy ofOral Medicine Web site]. June 1, 2010. Available at: http://www.aaom.com/ associations/3215/files/BurningMouthFinal762010.pdf
18. Ueda N, Kodama Y, Hori H, et al. Two cases ofburning mouth syndrome treated with olanzapine. Psychiatry Clin Neurosci 2008;62:359-361. (Pubitemid 351832314)
19. Pae CU. Milnacipran for chronic pain in the orofacial region. Clin Neuropharmacol 2010;33:270.